US20120064021A1 - Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent - Google Patents

Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent Download PDF

Info

Publication number
US20120064021A1
US20120064021A1 US13/231,466 US201113231466A US2012064021A1 US 20120064021 A1 US20120064021 A1 US 20120064021A1 US 201113231466 A US201113231466 A US 201113231466A US 2012064021 A1 US2012064021 A1 US 2012064021A1
Authority
US
United States
Prior art keywords
extract
skin
cosmetic composition
orchid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/231,466
Other languages
English (en)
Inventor
Virginie Leplanquais
Patrice Andre
Virginie Pecher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LVMH Recherche GIE
Original Assignee
LVMH Recherche GIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LVMH Recherche GIE filed Critical LVMH Recherche GIE
Assigned to LVMH RECHERCHE reassignment LVMH RECHERCHE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDRE, PATRICE, LEPLANQUAIS, VIRGINIE, PECHER, VIRGINIE
Publication of US20120064021A1 publication Critical patent/US20120064021A1/en
Priority to US14/836,322 priority Critical patent/US10172785B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/42—Colour properties
    • A61K2800/43—Pigments; Dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Definitions

  • the invention relates to a novel cosmetic composition, comprising at least one extract from the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient, in particular for preventing or delaying the appearance of the signs of skin ageing, for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
  • Skin ageing reveals itself in numerous changes intrinsic to the skin and the progressive appearance of visible signs which modify the beauty and the quality of the skin.
  • the skin texture is less fine, and numerous skin blemishes develop.
  • the ageing results in a progressive deterioration in biological mechanisms such as the slowing of the synthesis of structural proteins (collagen, elastin).
  • Apoptosis a type of programmed cell death, is an active biological process of elimination of cells from the body, by fragmentation and under genetic control.
  • the elimination can be natural (surplus cells in a tissue) or induced by various stresses.
  • the biological cascade of apoptosis is known and brings into play a number of effectors such as proteases of the caspase family.
  • IAP Inhibitors of apoptosis
  • survivin a bifunctional protein, capable of simultaneously controlling the apoptosis of cells and of regulating their cell cycle.
  • Survivin is a regulator of the survival and the resistance of the keratinocytes to the stresses that can induce this apoptosis phenomenon. It also regulates their capability for renewal and regeneration of the epidermis. It thus makes it possible to save the cellular capital of the epidermis and to maintain effective cell renewal (Dallaglio, et al., Experimental Dermatology, 18 (5) 464-72).
  • the production of survivin is tightly controlled by the mitochondrial protein Smac/DIABLO (Second Mitochondrial Activator of Caspases or Direct IAP Binding Protein with Low pI), liberated during apoptosis.
  • Smac/DIABLO Synthetic Mitochondrial Activator of Caspases or Direct IAP Binding Protein with Low pI
  • UV radiation or free radicals such as the ROS induce cell stress in the skin, a stress which is involved in skin ageing.
  • the mature mitochondrial protein Smac/DIABLO In response to stimuli such as UV radiation or reactive oxygen species (ROS), the mature mitochondrial protein Smac/DIABLO is released into the cell cytosol where it acts as an inhibitor of the IAP. In the form of dimers, it binds to the IAP and thus blocks the inactivation of the caspases (Kurita-Ochiai T et al, J. Dent. Res. 2010, 89(7), 689-694).
  • an orchid extract exhibits such an inhibitory effect on the expression of the protein smac/DIABLO, and more particularly an extract of flowers of the orchid Dendrobium chtysotoxum.
  • erianin has been isolated from an extract of stems of Dendrobium chtysotoxum (N G et al, Life Science, 2000, 66 (8), 709-23), a compound for which an antioxidant activity has been demonstrated in the rat.
  • the principal purpose of the invention is to provide novel cosmetic compositions, intended in particular to prevent or delay the appearance of the signs of skin ageing, or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity, this activity being obtained in particular by inhibition of the expression and/or the activity of mitochondrial protein Smac/DIABLO.
  • the inventors of the present invention have now demonstrated that the treatment of normal human keratinocytes (NHK) with at least one extract of an orchid of the species Dendrobium chrysotoxum , induces a significant decrease in the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
  • NHK normal human keratinocytes
  • This effect of inhibition of the expression and/or the activity of said protein results in a more intense activity of limitation of apoptosis of the cells and regulation of their cell cycle by the IAPs.
  • the invention relates to a cosmetic composition comprising said extract and to a cosmetic or dermatologic care method characterized in that it comprises the application of an effective quantity of a composition according to the invention onto the part of the skin of the face or the body concerned.
  • the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum , for preventing or delaying the appearance of the signs of skin ageing, or slowing or attenuating the effects thereof, or else also promoting cell or tissue longevity, in particular in that it inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO (extract of the invention), and its use as an active agent in cosmetic or dermatologic compositions
  • a first subject of the invention relates to a cosmetic composition, comprising at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient.
  • the cosmetic composition is more particularly intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
  • the extract of the invention advantageously inhibits the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
  • the plant material preferably consists only of flowers of the orchid Dendrobium chrysotoxum .
  • the invention also relates to combinations of the extract of the invention with any extract of another part of the orchid Dendrobium chrysotoxum , preferably prepared under the same conditions as the extract of the invention, or compound isolated from one of these extracts.
  • the extract of the invention can be prepared by different extraction processes known to those skilled in the art.
  • the extract is obtained by means of a polar solvent or a mixture of polar solvents.
  • a solvent or a mixture of solvents is advantageously selected from water, a C 1 -C 4 alcohol, for example ethanol, a C 2 -C 6 glycol, preferably selected from glycerol, butylene glycol and propylene glycol, or else also any mixture thereof.
  • the C 1 -C 4 alcohol is ethanol.
  • the plant material is extracted by means of a solvent comprising at least 50% v/v of ethanol and up to 100% v/v of ethanol, the balance if necessary consisting of another polar solvent and in particular of water.
  • the extraction can be performed hot under reflux or else at ambient temperature.
  • the extraction is effected by maceration of the plant material in a polar solvent or a mixture of polar solvents such as aforesaid, at ambient temperature for several hours.
  • the extract is a dry extract, possibly brought into solution.
  • the plant material Prior to the extraction step itself, the plant material may have been dried and/or ground and/or delipidated.
  • the delipidation of the extract can be effected by means of nonpolar solvents, such as for example a C 6 -C 7 alkane, or else also by CO 2 in the supercritical state, possibly with the addition of a polar co-solvent such as ethanol, methanol or else caprylic/capric triglycerides (Mygliol 812®, Hüls AG).
  • nonpolar solvents such as for example a C 6 -C 7 alkane
  • CO 2 in the supercritical state
  • a polar co-solvent such as ethanol, methanol or else caprylic/capric triglycerides (Mygliol 812®, Hüls AG).
  • the extraction can also, optionally, comprise at least one supplementary stage of decolourization or purification of the extract of the invention.
  • the decolourization of the extract can for example consist in a treatment of said extract with a nonpolar solvent of the type of those used to delipidate the extract.
  • the extraction can be completed by a stage of partial or total removal of the extraction solvents.
  • the extract is generally concentrated until an aqueous concentrate not containing a significant quantity of organic solvents is obtained, and in the second case a dry residue is obtained.
  • the product from the extraction stage can be lyophilized or atomized to take the form of a powder.
  • the extract is used in the dry state or else in solution or suspension in a solvent or a mixture of cosmetically acceptable solvents, which can be identical or different from that or those used for the extraction.
  • the cosmetic composition comprises an effective quantity of extract for obtaining the desired effect, in particular an inhibition of the expression and/or of the activity of the mitochondrial protein Smac/DIABLO.
  • the composition thus preferably comprises from 0.0001% to 1% by weight of dry extract, preferably from 0.001% to 0.01% by weight relative to the total weight of the composition.
  • the properties of the extract of the invention can also be obtained or improved in cosmetic compositions wherein the extract of the invention is combined with other cosmetically acceptable active agents, in the form of purified substances and/or extracts, in particular plant extracts, exhibiting cosmetic effects similar and/or complementary to those of said extract of the invention.
  • composition can thus comprise one or more other extracts of plants, and advantageously comprise at least one extract of another part of the orchid Dendrobium chrysotoxum or of another orchid or a substance purified from such an extract.
  • the cosmetic composition can also advantageously comprise one or more other active agents among those which stimulate the expression of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii , or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondasa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia oliveri, Lepechinia caulescens, Limnophila conferta , and any mixture thereof.
  • active agents among those which stimulate the expression of survivin such as forskolin or an extract containing these, in particular an extract of Coleus forskolii , or else also a plant extract obtained from a plant species selected from Nostoc commune, Butea frondasa, Neochloris oleabundans, Scenedesmus dimorphus, Curcuma longa, Crocus sativus, Daniellia olive
  • the cosmetic composition can comprise other cosmetically acceptable active agents selected from the group of substances having an anti-ageing activity, substances having a depigmenting, whitening or clearing activity on the skin, substances having a slimming activity, substances having a hydrating activity, substances having a calming, soothing or relaxing activity, substances having an activity stimulating the skin microcirculation to improve the lustre of the complexion, in particular of the face, substances having a sebo-regulatory activity for the care of oily skins, substances intended to clean or purify the skin, substances having an anti-radical activity, and any mixture thereof.
  • other cosmetically acceptable active agents selected from the group of substances having an anti-ageing activity, substances having a depigmenting, whitening or clearing activity on the skin, substances having a slimming activity, substances having a hydrating activity, substances having a calming, soothing or relaxing activity, substances having an activity stimulating the skin microcirculation to improve the lustre of the complexion, in particular of the face, substances having a sebo-regulatory activity for the
  • composition of the invention comprises at least one cosmetically acceptable excipient which may be selected from pigments, colorants, polymers, surface-active agents, viscosity agents, perfumes, electrolytes, pH adjusters, anti-oxidant agents, preservatives, and any mixture thereof.
  • cosmetically acceptable excipient may be selected from pigments, colorants, polymers, surface-active agents, viscosity agents, perfumes, electrolytes, pH adjusters, anti-oxidant agents, preservatives, and any mixture thereof.
  • the cosmetic composition can for example be a serum, a lotion, a cream, a hydrogel, preferably a mask, an oil-in-water emulsion, an anhydrous composition, or else be in the form of a stick, a patch, or in the form of a make-up product of the lipstick, mascara or foundation type.
  • the extract and the composition of the invention exhibit a particularly desired effect for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity.
  • a second subject of the invention thus relates to the use in a cosmetic composition of at least one extract of flowers of the orchid Dendrobium chrysotoxum as an active agent intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
  • the extract or the composition is as defined above or below.
  • composition comprising said extract is itself intended to prevent or delay the appearance of the signs of skin ageing or to slow or attenuate the effects thereof, or else also to promote cell or tissue longevity.
  • a third subject of the invention relates to a cosmetic care method, in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity, characterized in that it comprises the application of an effective quantity of a cosmetic composition as defined above onto at least one part of the skin of the face or the body.
  • the cosmetic composition is applied onto a skin zone of the body or the face exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
  • the invention also relates to the use of an effective amount of at least one extract of flowers of the orchid Dendrobium chrysotoxum , for the preparation of a composition for preventing or delaying the appearance of the signs of intrinsic and/or extrinsic ageing of the skin, or for slowing down the effects thereof.
  • the composition can be especially applied via topical application to at least one area of skin of an individual exhibiting visible signs of ageing such as the presence of wrinkles or small wrinkles or a loss of lustre of the skin complexion, or other signs such as a loss of elasticity and/or suppleness of the skin, a decrease in the thickness of the skin, and/or an increase in skin dryness or roughness.
  • the composition is especially intended to be applied on the skin of an individual being over 35 years old, over 40 years old, over 45 years old, over 50 years old, over 55 years old or even over 60 years old.
  • the composition can advantageously be applied on mature skins. It can be specifically intended to prevent or delay the appearance of the signs of ageing of the skin of the face and/or of the eyes.
  • a fourth subject of the invention relates to an orchid extract, in particular of the species Dendrobium chrysotoxum , inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.
  • the extract is advantageously an extract of flowers of Dendrobium chrysotoxum as defined above.
  • the extract is moreover advantageously obtained by means of a polar solvent or a mixture of polar solvents as described above.
  • said extract is a dry extract, possibly brought into solution.
  • FIG. 1 represents the level of expression of the mitochondrial protein Smac/DIABLO (expressed in pg/ ⁇ g total proteins), measured by an immuno-enzymatic method, after treatment of normal human keratinocytes (NHK) with one of the extracts prepared in Example 1 (S-1 to S-4) and compared with a solvent control (T-SO) and a positive control (T+). The percentages indicated correspond to the percentages inhibition relative to the solvent control (T-SO).
  • the plant material of extracts S-1, S-2, 5-3 and 5-4 consisted of flowers of the orchid Dendrobium chrysotoxum .
  • the extracts R and G were obtained from roots of the Dendrobium chrysotoxum orchid or from the leaves of the Grammatophyllum sp. orchid.
  • the plant material in a dry state and ground, was subjected to an aqueous alcohol extraction with 90/10 v/v ethanol/water under reflux for 30 minutes in order to prepare extracts 5-1, R and G.
  • the extraction solvent was then removed to obtain a dry extract.
  • the extracts prepared and their associated extraction yield expressed as percentage (weight/weight) of dry extract relative to the starting plant material in the dry state and ground are summarized below.
  • Extract code Type of extraction Extraction yield S-1 Ethanol/water 90/10 v/v - reflux 23.1% S-2 Ethanol 100% - reflux 17.0% S-3 Ethanol/water 70/30 v/v - AT 27.9% S-4 Ethanol/water 50/50 v/v - AT 28.4% R Ethanol/water 90/10 v/v - reflux 14.7% G Ethanol/water 90/10 v/v - reflux 14.1%
  • Example 2 For the cosmetic activity tests of Example 2 below, a stock solution was prepared for each extract, in which the dry extract was dissolved in DMSO at the concentration of 12.5 mg of extract per mL of solvent.
  • Forskolin is a known activator of the expression of survivin (cf. example 1 of the patent application FR2932086).
  • an extract of Coleus forskolii which contains at the minimum 98% by weight of forskolin was used as the positive control.
  • Such an extract is marketed in the form of powder for example by SIGMA.
  • the solution of the positive control thus prepared was added to the culture medium so as to obtain a dilution to one thousandth, i.e. a forskolin concentration equal to about 10 ⁇ 9 M.
  • DMSO solvent control
  • the stock solution of each extract tested (S-1 to 5-4, R and G) was diluted in the keratinocyte culture medium in order to obtain a final concentration of extract of 12.5 ⁇ g/mL.
  • the cultured NHK were inoculated into 48-well microplates in an amount of 50,000 cells per well, in complete serum-free culture medium (KSFMc, Gibco).
  • This first culturing day corresponds to D0.
  • the treatment stage started on D1, after 24 hours of incubation (37° C., 5% CO 2 ) of the NHK.
  • the NHK were lysed on a half plate in order to perform the assays (lysis buffer prepared extemporaneously according to the protocol described in the Smac/DIABLO protein assay kit (ref. below).
  • the other half plate was rinsed with PBS and then stored at ⁇ 20° C. in order to assay the total proteins therein by a colorimetric test according to the BCA method (BC Assay Kit, Uptima Interchim) by absorbance measurement at 570 nm.
  • the level of Smac/DIABLO produced by the keratinocytes was evaluated with the Duoset Smac/DIABLO ELISA kit (R&D Systems).
  • HRP horseradish peroxidase
  • the absorbance was measurable at a wavelength of 450 nm.
  • a standard range was created on the basis of dilutions of a standard stock solution of Smac/DIABLO, provided in the kit.
  • the percentages inhibition of the production of this protein were calculated relative to the basal level without treatment (TSO).
  • the positive control is forskolin (FSK).
  • the root extract of Dendrobium chrysotoxum and the leaf extract of Grammatophyllum sp. do not have a significant inhibiting effect on the expression of the Smac/DIABLO protein.
  • the difference in concentration in the protein with the DMSO indicator is no more than ⁇ 9% for the Dendrobium chrysotoxum root extract and ⁇ 13% for the Grammatophyllum sp. leaf extract.
  • the extracts of the invention which can be obtained by extraction processes using polar solvents, were formulated as anti-ageing active agents in cosmetic compositions, and in particular for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects, or else also for promoting cell or tissue longevity.
  • the dry extract was dissolved at 2% w/w in a 60/40 v/v glycerol/water mixture.
  • Pentylene glycol 3 Glyceryl stearate 3
  • Cetyl alcohol 1 Stearyl alcohol 1 Dimethicone 1
  • phase A The excipients of phase A were dispersed in water, then heated to 80° C., before dissolving all the other compounds including the water-glycol solution of Dendrobium chrysotoxum extract.
  • phase B The compounds of phase B were heated to 85° C. to form a homogeneous phase.
  • Phase A was emulsified in phase B by means of an Ystral mixer.
  • phase C the oil-in-water emulsion thus obtained was neutralized by means of a 0.04% w/w solution of sodium hydroxide (phase C), then cooled.
  • composition obtained is an anti-ageing cream intended to be applied onto all or part of the face.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cosmetics (AREA)
US13/231,466 2010-09-14 2011-09-13 Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent Abandoned US20120064021A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/836,322 US10172785B2 (en) 2010-09-14 2015-08-26 Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1057336A FR2964567B1 (fr) 2010-09-14 2010-09-14 Extrait d'orchidee
FR1057336 2010-09-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/836,322 Division US10172785B2 (en) 2010-09-14 2015-08-26 Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent

Publications (1)

Publication Number Publication Date
US20120064021A1 true US20120064021A1 (en) 2012-03-15

Family

ID=43430793

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/231,466 Abandoned US20120064021A1 (en) 2010-09-14 2011-09-13 Dendrobium chysotoxum extract and its cosmetic use as an anti-aging agent
US14/836,322 Expired - Fee Related US10172785B2 (en) 2010-09-14 2015-08-26 Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/836,322 Expired - Fee Related US10172785B2 (en) 2010-09-14 2015-08-26 Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent

Country Status (8)

Country Link
US (2) US20120064021A1 (zh)
JP (1) JP5900845B2 (zh)
KR (1) KR101932766B1 (zh)
CN (1) CN102397184B (zh)
DE (1) DE102011053521A1 (zh)
FR (1) FR2964567B1 (zh)
GB (1) GB2483766B (zh)
IT (1) ITTO20110816A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040395A2 (en) * 2011-09-14 2013-03-21 Nefeli Corp. Herbal skin care composition
US10144952B2 (en) 2013-03-18 2018-12-04 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US10676780B2 (en) 2011-09-26 2020-06-09 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
US10724074B2 (en) 2012-09-25 2020-07-28 Qiagen Gmbh Stabilisation of biological samples
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US11203777B2 (en) 2015-11-20 2021-12-21 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
CN114081853A (zh) * 2021-03-26 2022-02-25 太和康美(北京)中医研究院有限公司 一种植物组合物及其制备方法和应用
US11525155B2 (en) 2013-03-18 2022-12-13 Qiagen Gmbh Stabilisation of biological samples

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877080B1 (en) 2012-07-26 2020-07-22 DePuy Synthes Products, Inc. Ycbcr pulsed illumination scheme in a light deficient environment
CN103239471A (zh) * 2013-05-21 2013-08-14 广州中医药大学 一种润肤外用制剂
CN105853289A (zh) * 2016-05-05 2016-08-17 广州丹奇日用化工厂有限公司 含有石斛提取物的化妆品组合物及其应用
CN106691949A (zh) * 2017-02-27 2017-05-24 广东黑霸生物科技有限公司 具有黑发功效的中药提取液及其制备方法和应用
CN109875937A (zh) * 2017-12-06 2019-06-14 伽蓝（集团）股份有限公司 石斛提取物的应用
CN108042458B (zh) * 2018-01-10 2021-11-23 中国科学院昆明植物研究所 美花石斛提取物及其在制备化妆品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02279618A (ja) * 1989-04-20 1990-11-15 Ichimaru Pharcos Co Ltd ラン科植物抽出物含有化粧料
JP4880816B2 (ja) * 2000-12-15 2012-02-22 株式会社ヤクルト本社 皮膚老化防止剤
JP2002205933A (ja) * 2001-01-05 2002-07-23 Ichimaru Pharcos Co Ltd ラン科植物抽出物含有化粧料組成物
DE102004010645A1 (de) * 2003-04-24 2004-11-11 Coty B.V. Kosmetikum zur Depigmentierung
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
FR2924348B1 (fr) * 2007-11-30 2010-11-26 Lvmh Rech Composition contenant un extrait de l'orchidee vanda teres.
FR2928549B1 (fr) * 2008-03-13 2013-07-26 Lvmh Rech Utilisation d'un extrait de l'orchidee brassocattleya marcella koss en tant qu'actif pour prevenir ou retarder l'apparition des signes du vieillissement cutane
FR2932086A1 (fr) * 2008-06-06 2009-12-11 Lvmh Rech Methode de soin cosmetique anti-age par stimulation de l'expression de la survivine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Can we prevent aging". Retrieved from the Internet on: 2012-11-16. Retrieved from: . *
(U1) forskolin 2005http://web.archive.org/web/20051024120013/http://www.advance-health.com/coleus.html *
Brannon, H. Retrieved from the Internet on: 2012-12-03. Retrieved from:. *
Sastre et al.The Role of Mitochondrial Oxidative Stress in Aging, 2003, Free Radic Biol Med, 35: 1-8 *
Stibich, Mark. "Free Radical Theory of Aging". Web Update date: 2014-08-14 [Retrieved from the internet on: 2015-03-21]. Retrieved from: . *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040395A2 (en) * 2011-09-14 2013-03-21 Nefeli Corp. Herbal skin care composition
WO2013040395A3 (en) * 2011-09-14 2013-05-10 Nefeli Corp. Herbal skin care composition
US9192643B2 (en) 2011-09-14 2015-11-24 Nefeli Corp. Herbal skin care composition
US9272012B1 (en) 2011-09-14 2016-03-01 Nefeli Corp. Herbal skin care composition
US10676780B2 (en) 2011-09-26 2020-06-09 Qiagen Gmbh Stabilisation and isolation of extracellular nucleic acids
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US10724074B2 (en) 2012-09-25 2020-07-28 Qiagen Gmbh Stabilisation of biological samples
US10144952B2 (en) 2013-03-18 2018-12-04 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
US11525155B2 (en) 2013-03-18 2022-12-13 Qiagen Gmbh Stabilisation of biological samples
US11203777B2 (en) 2015-11-20 2021-12-21 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
CN114081853A (zh) * 2021-03-26 2022-02-25 太和康美(北京)中医研究院有限公司 一种植物组合物及其制备方法和应用

Also Published As

Publication number Publication date
US20150359733A1 (en) 2015-12-17
JP5900845B2 (ja) 2016-04-06
FR2964567A1 (fr) 2012-03-16
GB2483766B (en) 2013-02-13
CN102397184B (zh) 2016-02-03
KR101932766B1 (ko) 2018-12-26
ITTO20110816A1 (it) 2012-03-15
CN102397184A (zh) 2012-04-04
KR20120028238A (ko) 2012-03-22
JP2012067098A (ja) 2012-04-05
DE102011053521A1 (de) 2012-03-15
FR2964567B1 (fr) 2013-03-15
US10172785B2 (en) 2019-01-08
GB201115497D0 (en) 2011-10-26
GB2483766A (en) 2012-03-21

Similar Documents

Publication Publication Date Title
US10172785B2 (en) Dendrobium chrysotoxum extract and its cosmetic use as an anti-aging agent
RU2545708C2 (ru) Экстракт цельных семян moringa sp. и его применение в косметических и/или дерматологических композициях
US8771758B2 (en) Use of Tiliacora triandra in cosmetics and compositions thereof
US11213479B2 (en) Cosmetic composition comprising a passionflower extract and edelweiss cells, and uses
KR101824770B1 (ko) 적하수오 부정근 추출물을 함유하는 피부 주름개선 기능성 화장료 조성물
CA2799083C (en) Use of tiliacora triandra in cosmetics and compositions thereof
US20190328650A1 (en) Cosmetic use of the essential oil of laserpitium siler l. against the signs of aging of the skin and as a skin antioxidant
JP5626650B2 (ja) ラン抽出物を含有する化粧品用組成物
KR20160091300A (ko) 피부 노화 징후의 출현을 방지 또는 지연시키기 위한 활성제로서의 브라소카틀레야 마르셀라 코스 난초 추출물의 용도
KR20090127240A (ko) 서바이빈 발현의 자극에 의한 항-노화 미용 관리 방법
KR20080107565A (ko) 백리향 추출물을 유효성분으로 함유하는 화장료 조성물
KR20130057091A (ko) 흰감국 추출물을 함유하는 피부 외용제 조성물
KR100561036B1 (ko) 설련 추출물 및 권백 추출물을 유효성분으로 함유하는피부외용제 조성물
KR101027113B1 (ko) 해송의 송기 추출물을 함유하는 화장료 조성물의 제조방법
US20130028849A1 (en) Agent For Stimulating The Expression of Loxl
KR100903654B1 (ko) 하고초 추출물과 아데노신을 함유하는 화장료 조성물
KR20090089982A (ko) 시로미 추출물을 포함하는 피부주름 개선효과를 갖는화장료 조성물
KR102533787B1 (ko) 물고사리의 플라보노이드와 폴리페놀 성분에 대한 항산화 효과 및 피부 노화 방지, 또는 피부 주름 예방 또는 개선용 화장료 조성물
KR102370802B1 (ko) 민들레 뿌리 추출물, 카페인 및 토코페롤의 혼합물을 포함하는 피부 외용제 조성물
KR20050038381A (ko) 금등화 추출물 또는 비자 추출물로부터 선택된 1종 이상을주요 활성성분으로 함유하는 피부외용제 조성물
KR20230010994A (ko) 피부의 주름 개선, 미백, 세포 재생, 상처 치유에 유효한 피트 추출물과 소금을 활성성분으로 함유하는 다 기능성 화장품 조성물
KR20190107454A (ko) 가시연꽃 씨 추출물을 유효성분으로 포함하는 피부 노화 방지 및 피부 장벽 기능 강화용 조성물
KR20110037463A (ko) 노루풀 추출물과 아데노신을 함유하는 피부 주름 개선용 화장료 조성물
KR20150065028A (ko) 베취 나무 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: LVMH RECHERCHE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEPLANQUAIS, VIRGINIE;ANDRE, PATRICE;PECHER, VIRGINIE;REEL/FRAME:027137/0464

Effective date: 20111025

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION